Travere Therapeutics, Inc.

Travere Therapeutics is a biopharmaceutical company that identifies, develops, and commercializes therapies for rare kidney and metabolic diseases. The company's lead product is FILSPARI, an oral medication that treats immunoglobulin A nephropathy and focal segmental glomerulosclerosis by blocking pathways that cause kidney damage; it also markets Thiola and Thiola EC for cystinuria, a rare genetic disorder. The company generates revenue from its commercialized products and reinvests proceeds into a pipeline of late-stage candidates, including pegtibatinase for homocystinuria, while leveraging a specialized sales force focused on nephrologists and rare-disease prescribers, direct-to-patient pharmacy partnerships, and international distribution agreements with established pharmaceutical partners in key markets.